Press Releases

 
Press Releases
  Date Title and Summary View
Dec 4, 2016
• 100 Percent of Responders Tested Negative for Minimal Residual Disease (MRD) SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite Pharma, Inc. (Nasdaq:KITE) today announced that 82 percent of patients (9 out of 11) achieved complete remission or complete remission wi...
Dec 1, 2016
Company Strengthens Supply Chain Operations as it Prepares for Potential Approval and Launch of KTE-C19 for Aggressive non-Hodgkin Lymphoma by the U.S. Food and Drug Administration in 2017 SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite Pharma, Inc. (Nasdaq: KITE) today a...
Nov 21, 2016
KTE-C19 Significantly Improved Objective Response Rate in Patients with Chemorefractory DLBCL at Pre-Defined Interim Analysis Represents One of Only Six Abstracts Accepted as a Late-Breaking Presentation SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kit...
Nov 9, 2016
Company Announces Plans to Initiate a Rolling Submission of the Biologics License Application for KTE-C19 with the U.S. Food and Drug Administration for an Expanded Indication of Aggressive Non-Hodgkin Lymphoma in December 2016 with a Targeted Completion in Q1 2017 Potential Approval a...
Nov 3, 2016
Oral Presentation on Novel T cell Manufacturing Process for KTE-C19 in Acute Lymphoblastic Leukemia (ALL) Poster Presentation of Preliminary Safety and Efficacy Data from the Phase 1 Portion of ZUMA-3 and ZUMA-4 Trials in Adult and Pediatric Patients with Relapsed/Refractory (R/R) ALL ...
Nov 2, 2016
Conference Call and Webcast Scheduled for 8:30 AM PT/11:30 AM ET SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite Pharma, Inc. (Nasdaq:KITE) today announced that it will report third quarter 2016 financial results on Wednesday, November 9, 2016, prior to the open of the market. The announcement ...
Oct 28, 2016
SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite Pharma, Inc. (Nasdaq:KITE) today announced that management will present at three investor conferences in November: • Credit Suisse 25th Annual Healthcare Conference Date: Monday, November 7, 2016 ...
Oct 19, 2016
Four New Clinical Programs Unveiled to Drive Long-Term Growth T cells 2.0 Next Generation Programming to Realize Full Potential of Cell Therapy KTE-C19 Expansion Studies with the Potential to Deliver Six Additional Indications in B-cell Malignancies ...
Oct 13, 2016
SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite Pharma, Inc. (Nasdaq:KITE) today announced the appointment of Chris Nowers as its Head of Europe. Nowers will be based in London. In his new role, Nowers will oversee European commercial operations to build awareness in the region of Kite's growing pipeline portfolio o...
Oct 11, 2016
SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite Pharma, Inc. (Nasdaq:KITE) today announced that it will hold an Investor Day on October 18, 2016 in New York where the company will share updates on its advancing pipeline of chimeric antigen receptor (CAR) and T cell receptor (TCR) product candidates, next generation ...
Page: FirstPrevious
3
... NextLast
= add release to Briefcase